1J. W. Paxton,S. E. Foote,R. M. Singh. The effect of buthionine sulphoximine, cimetidine and phenobarbitone on the disposition of amsacrine in the rabbit[J] 1986,Cancer Chemotherapy and Pharmacology(3):208～212
2James W. Paxton,Jeffrey L. Jurlina. Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino]-4-acridinecarboxamide in rabbits[J] 1986,Cancer Chemotherapy and Pharmacology(3):253～256
3J. L. Jurlina,A. R. Varcoe,J. W. Paxton. Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia[J] 1985,Cancer Chemotherapy and Pharmacology(1):21～25
4David J. Stewart,Guo Zhengang,Katherine Lu,Niramol Savaraj,Lynn G. Feun,Mario Luna,Robert S. Benjamin,Michael J. Keating,Ti Li Loo. Human tissue distribution of 4′-(9-acridinylamino)-methanesulfon-m-anisidide (NSC 141549, AMSA)[J] 1984,Cancer Chemotherapy and Pharmacology(2):116～119
5A. Emonds,O. Driessen,E. A. Bruijn,A. T. Oosterom. Gas-chromatographic determination of amsacrine (AMSA) in plasma[J] 1981,Fresenius’ Zeitschrift für Analytische Chemie(4):286～287
